Fiona H. Blackhall

Fiona H. Blackhall

Wilmslow Road
Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 199 publications

Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.

Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 08, 2026

Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis.

Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 10, 2026

New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC.

New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 19, 2026

Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project.

Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 04, 2025

Small-cell lung cancer: anatomy of an immune-cold tumor.

Small-cell lung cancer: anatomy of an immune-cold tumor.

Journal: Trends in cancer

Published: August 08, 2025

Matching-Adjusted Indirect Treatment Comparison of Tarlatamab Versus Comparator Therapies in England in Patients with Extensive-Stage Small Cell Lung Cancer Who Have Received Two or More Prior Lines of Therapy.

Matching-Adjusted Indirect Treatment Comparison of Tarlatamab Versus Comparator Therapies in England in Patients with Extensive-Stage Small Cell Lung Cancer Who Have Received Two or More Prior Lines of Therapy.

Journal: Advances in therapy

Published: July 25, 2025

Evolutionary characterization of lung cancer metastasis.

Evolutionary characterization of lung cancer metastasis.

Journal: Nature

Published: June 29, 2025

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.

Journal: The New England journal of medicine

Published: June 02, 2025

External evaluation of the Manchester score in a contemporary SCLC cohort.

External evaluation of the Manchester score in a contemporary SCLC cohort.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 22, 2025

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Journal: Cancer discovery

Published: May 21, 2025

Overall survival by baseline and on-treatment systemic immune-inflammation index in patients with advanced cancer receiving immune checkpoint inhibitors: a large single-centre cohort study.

Overall survival by baseline and on-treatment systemic immune-inflammation index in patients with advanced cancer receiving immune checkpoint inhibitors: a large single-centre cohort study.

Journal: Immunotherapy advances

Published: May 15, 2025

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 12, 2025

Showing 1-12 of 199

Last Updated: 09/26/2026